BioCentury
ARTICLE | Politics & Policy

Payers vs. drug makers on HCV drug costs

July 30, 2014 1:12 AM UTC

Dueling reports released by groups representing drug makers on one side and payers on the other, highlight the benefit of new HCV treatments as well as the cost. Sovaldi sofosbuvir from Gilead Science...